Shandong Bailong Chuangyuan Bio-Tech Co. Ltd.

Bailong Chuangyuan announced that, based on its strategic development plan, it will use its own funds of 10 million yuan to establish a wholly-owned subsidiary in Kunming, Bailong Chuangyuan Kunming Biotechnology Co., Ltd., with 100% shareholding. The subsidiary will mainly engage in the sale of food additives, feed additives, health food, and import and export of goods. The company's products include isomaltooligosaccharide, fructooligosaccharide, allulose, and others, which are sold widely in overseas markets. Overseas markets are an important source of revenue for the company. The establishment of the Kunming subsidiary aims to efficiently connect with the Thailand production base by leveraging the China-Laos Railway as a golden corridor, creating a synergistic structure of a Kunming operations hub plus a Thailand production base, reducing cross-border logistics costs, and enhancing customer service capabilities in the Southeast Asian region.

Bailong Chuangyuan released its 2026 interim report, with total operating revenue of 759 million yuan, net profit attributable to the parent company of 211 million yuan, and net cash inflow from operating activities of 441 million yuan. The company's latest asset-liability ratio is 26.56%, up 0.93 percentage points from the previous quarter and up 4.26 percentage points from the same period last year. Gross margin is 43.72%, down 1.38 percentage points from the previous quarter, ROE is 10.02%, and diluted earnings per share is 0.50 yuan. Total asset turnover is 0.29 times, down 4.31% year-on-year, and inventory turnover is 1.39 times, down 27.42% year-on-year. The number of shareholders is 11,800, and the top ten shareholders hold 280 million shares, accounting for 66.71% of the total share capital.